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 Primary cilia - an in vitro model to evaluate Tthe toxic effect of cytostatics on on 
primary cilia frequency and multiciliationcytoskeletal stability.
Therefore, the increased primary cilia frequency induced by cytostatics could be used in other 
studies trying to assess the toxicity of these drugs.
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The primary cilium is considered as a key component of morphological cellular 
stability. However, cancer cells are notorious for lacking primary cilia in most cases, 
depending upon the tumour type. Previous reports have shown the effect of starvation and 
cytostatics on ciliogenesis in normal and cancer cells although with limited success, especially 
when concerning the latter. In this study we evaluated the presence and frequency of primary 
cilia in breast fibroblasts and in triple negative breast cancer cells after treatment with 
cytostatics finding that, in the case of breast fibroblasts, primary cilia were detected at their 
highest incidence 72 hours after treatment with 120 nM doxorubicin. Further, multiciliated 
cells were also detected after treatment with 80 nM doxorubicin. On the other hand, treatment 
with taxol increased the number of ciliated cells only at low concentrations (1.25 and 3.25 
nM) and did not induce multiciliation. Interestingly, triple negative breast cancer cells did not 
present primary cilia after treatment with either doxorubicin or taxol. This is the first study 
reporting presence of multiple primary cilia in breast fibroblasts induced by Doxorubicin. 
However, the null effect of these cytostatics on primary cilia incidence in the evaluated TNBC 
cell lines requires further research. 
These results suggest that primary cilia could be involved in specific cell signalling events 
and cytoskeletal stability after chemotherapy, although further research is needed in this 
regard. 
Key words: Primary cilium, multiple cilia, cytostatics, toxicity, cell line triple negative breast 
cancer.
































































Primary cilium, an organelle found on nearly every cell in the human body, typically serves as 
a mechanical sensory tool; further, it is also involved in cell proliferation and embryonic 
development. This organelle is dynamically regulated during the cell cycle, appearing during 
the G0/G1 phases and resorbed prior to mitosis [1] . The exact solubilization moment of 
primary cilia is determined by cell type and the expression of genes affecting resorption, such 
as Aurora A, Plk1, TcTex-1 [2, 3] . Usually, a cell has only one primary cilium which, as 
previously mentioned, is involved in morphogenesis, cell proliferation and differentiation 
signalling [4, 5] . Should there be a multiplication of centrosomes, a higher number of 
primary cilia will appear on the surface of cells as well, often bearing the same length and 
construction design, and spawning from the same ciliary pocket; however, the presence of 
multiple cilia has been mostly recorded in solid tumours [6, 7]  after exposure to ionizing 
irradiation [8, 9]  or in ciliopathies [10] . Typically, primary cilia are always observed in 
myoepithelial cells and fibroblasts and with low incidence in luminal epithelium cells. 
Regarding cancer cells, a study of 26 breast cancer biopsy samples revealed the presence of 
primary cilia only on exceptional cases, especially in epithelial cells [11] . 
Basal subtype B tumours, a classification of triple negative breast carcinomas (TNBC), is 
characterized by the absence of oestrogen, progesterone, and Her2/neu receptors [12], as well 
as by the rare presence of primary cilia. Among breast cancer tumours, TNBC has an 
estimated incidence of 10-20%, although from a histological point of view TNBCs are little 
differentiated and are often included in basal-like subgroups. From a clinical standpoint, these 
tumours are frequently resistant to treatment, have quick progression, low 5-year survival rate, 
increased local recurrence, and are highly metastatic. This kind of tumours can be observed at 
any age; however, they mostly occur accompanied by BRCA1 mutations in younger women 
(>40 years of age) [13]. Chemotherapy is the treatment of choice for triple negative breast 
cancer patients, of which Doxorubicin and Taxol are the standard chemotherapeutic agents 
used as anticancer therapy in combination with α-HER2/neu receptor targeted therapy. 
Doxorubicin belongs to the anthracyclines group, whereas Taxol is considered as a taxane. 
The former is an effective intercalating cytotoxic agent used in the treatment of various 
tumour types and commonly used in combination with the latter in adjuvant and neoadjuvant 
therapeutic strategies for breast cancer patients [14] . 































































Previous research on the effect of cytostatics on primary cilia has focused in the effects of 
Taxol over the elongation and shortening of primary cilia. In a study by Sharma et al., Taxol 
was shown to block the emergence of primary cilia in mammalian cell cultures [15]. 
However, low concentrations result in an increased quantity of free tubulin subunits in the 
cytosol, leading to enlarged primary cilia [16, 17]. Ongoing research highlights two important 
questions in the cell biology of cancer and primary cilia: 1) the significance of having primary 
cilia in normal cells, and 2) the loss of primary cilia in cancer cells and its relation to drug 
resistance [18] . Therefore, the increased primary cilia frequency induced by cytostatics could 
be used in other studies trying to assess the toxicity of these drugs. 
2 Material and methods
2.1 Cell culture
Unless otherwise stated, all standard chemicals and antibodies were purchased from Sigma-
Aldrich, Czech Republic. In this study, TNBC cell lines BT-549 (ATCC, USA) and MDA-
MB-231 were used (kindly supplied by Mgr. Jaroslav Truksa, Ph.D., Laboratory of Tumor 
Resistance, Institute of Biotechnology CAS, Prague), as well as skin fibroblasts. BT-549 cells 
were cultured in DMEM 10% FBS (PAA, USA), 2% glutamine (Gibco, UK), 1% 
penicillin/streptomycin (Gibco, UK), 0.023 IU/ml insulin and incubated in a 5% CO2 
atmosphere at 37°C. MDA-MB-231 and fibroblasts were cultured in DMEM, 10% FBS 
(PAA, USA), 2% glutamine (Gibco, UK), 1% penicillin/streptomycin (Gibco, UK) and 
incubated in a 5% CO2 atmosphere at 37°C. All cell lines were used until 10th to 12th passage 
and medium was replaced every two days for all experiments.
2.2 Skin fibroblasts
Human fibroblasts were isolated from skin biopsies obtained in accordance and approved by 
the Ethics Committee of the University Hospital Hradec Kralove, Czech Republic and the 
European Ethics committee under the directive approved on 10th July 2014 (Reference/license 
number: 201407 S12P). Donor patients signed an informed consent allowing us to work with 
the obtained samples. To isolate the fibroblasts, skin biopsies were kept in a basic solution (30 
ml/2g of tissue) after surgery and transported to the laboratory, where the biopsies were 
washed in PBS and the subcutaneous tissue was removed. Each individual tissue sample was 
incubated in 5 ml of a 2U/ml dispase solution (Gibco, UK) for 18 hours at 4°C. After 































































incubation, the samples were washed 3 times in PBS at room temperature (22°C). The dermis 
was separated from the epidermis using tweezers, washed in PBS and cut into small sections 
(<5mm2). Afterwards, the tissue was incubated in 10 ml of digestion solution (1g tissue/10 
ml) in a rotating incubator at 37°C/6 g. After 4 hours, the samples were filtered through a 40 
μm strainer into a new sterile 50 ml tube. The cell number was determined from this 
suspension and centrifuged for 10 min/150 g. The supernatant was decanted and the cell pellet 
was resuspended in culture media, plated in a T-75 flask (1x105 cells per flask) and incubated 
in a 5% CO2 atmosphere at 37°C for 14 days.
2.3 Cytostatic drugs
Doxorubicin and Taxol were dissolved in 0.5% DMSO and kept in 1 mM stock solutions. 
Doxorubicin and Taxol were diluted in culture media before use at a ratio of 1:100 and 
1:1000, respectively.
2.4 Cell treatment and Immunofluorescence
MDA-MB-231, BT-549, and fibroblasts cells were cultured in 6-well plates at a density of 3 x 
105 cells per well and incubated at 37°C/5% CO2 for 24h, each well contained a gelatine 
coated coverslip. After this period, the cells were treated with Doxorubicin (10, 20, 40, 80 and 
120 nM) or Taxol (1.25, 3.25, 5.25, 6.25, and 12.5 nM) for 72 hours. Control cells were kept 
under the same conditions in culture media with or without DMSO (0.5%). After treatment, 
the cells were fixed with 4% paraformaldehyde for 10 min at room temperature and washed 
three times with PBS. Immunostaining was performed as follows: cells were blocked with 
goat serum (Jackson Immunoresearch, USA) 1:20 for 30 minutes; anti-acetylated tubulin 
1:800 for 1 hour; anti-gamma tubulin  1:500 for 1 hour; Cy3-conjugated donkey anti-mouse 
secondary antibody 1:300 for 45 minutes in the dark; Alexa 488 conjugated donkey anti-
rabbit secondary antibody (JacksonImmunoresearch, USA) 1:300 for 45 min in the dark. 
Imaging analysis was performed using a Nikon Eclipse fluorescence microscope (Prague, 
Czech Republic) observed with an oil-immersion 60X objective. All experiments were 
performed in triplicate.
2.5 Cytotoxicity test
A WST-1 test (Roche; Basel, Switzerland) was used to determine cell viability after treatment 
with Doxorubicin (10, 20, 40, 80, 120 nM) or Taxol (1.25, 3.25, 5.25, 6.25, 12.5 nM). All cell 
lines were plated and treated in a 96-well-plate (1 x 103 cells per well), and incubated at 
37°C/5%CO2 for 24h. After 72 h, 10µL of WST-1 reagent was added and incubated for 3 h at 































































37°C/5% CO2 and analysed in a Tecan SpectraFluor Plus spectrometer (Tecan Austria GmbH; 
Grödig, Austria) at a wavelength of 440 nm. All experiments were performed in triplicate.
2.6 Transmission electron microscopy (TEM)
Fibroblasts were fixed in 3% glutaraldehyde (in 0.1 M cacodylate buffer, pH 7.2) for 5 min. at 
37°C and then for 3 h at room temperature, washed in cacodylate buffer (0.1 M, pH 7.2) and 
post-fixed in 1% OsO4 (in 0.1 M cacodylate buffer, pH 7.2) for 1 h at room temperature. 
After rinsing in cacodylate buffer (0.1 M, pH 7.2), the cells were dehydrated in graded 
alcohols (50%, 75%, 96%, 100%), cleared in propylene oxide and embedded in a mixture of 
Epon 812 and Durcupan (Sigma; polymerization for 3 days at 60°C). Semi-thin sections were 
stained with toluidine blue. Ultra-thin sections were cut on an Ultrotome Nova (LKB, 
Sweden), mounted into formvar carbon-coated copper grids, counterstained with uranyl 
acetate and lead citrate and examined in a JEOL JEM-1400Plus transmission electron 
microscope (at 120 kV JEOL, Japan). Images were captured with integrated 8Mpix CCD 
camera and software (JEOL, Japan).
2.7 Statistical analysis
Graphs were made using the GraphPad Prism 6 biostatistics software (GraphPad Software, 
USA). The statistical analysis between the evaluated groups was performed using one-way 
ANOVA followed by a post-hoc Tukey test (p<0.05).
3 Results
3.1 Proliferation and viability of BT-549, MDA-MB-231, and fibroblasts after 
treatment with Doxorubicin and Taxol 
Cytostatics are known inhibitors of cell viability and proliferation, therefore we had to 
determine a suitable concentration in which the cells would stop proliferating without losing 
viability. To achieve this purpose, the MDA-MB-231, BT-549 and fibroblast cells were 
maintained with Doxorubicin or Taxol at various concentrations (10, 20, 40, 80 and 120 nM 
and 1.25, 3.25, 5.25, 6.25 and 12.5 nM, respectively), followed by a WST-1 test after 72 
hours of treatment. The number of living cells was significantly lower after Doxorubicin 
(Figure 1A-C) and Taxol (Figure 1D-F) treatment across all cell lines.































































3.2 Primary cilia incidence and multi-ciliation induced by the cytostatics 
Doxorubicin and Taxol
Regarding Doxorubicin, the number of fibroblasts cells with primary cilia increased to ~70%,, 
when comparedin comparison with to control untreated cells, within after 72 hours of 
treatment with various concentrations of this cytostatic (10, 20, 40, 80 and 120 nM), 
observing a higher incidence after treatment with 120 nM Doxorubicin. Overall, this effect 
could be observed evenly across the entire dosage dose range used in this study (Figure 2A). 
After 72 hours of treatment, primary cilia were detected by immunostaining (Figure 2B – 
control cells; Figure 2C – 120nM Doxorubicin) and electron microscopy (Figure 2D – 
control; Figure 2E – 120 nM Doxorubicin). Interestingly, Approximately ~20 to -40% of 
fibroblasts treated with 20-120 nM Doxorubicin showed two or more cilia after 72 hours of 
treatment, observing a higher number of multi-ciliated cells at a dose of 80 nM Doxorubicin 
(~40%; Figure 3A). However, no multi-ciliated cells could be observed after treatment with 
10 nM Doxorubicin or in the control untreated cells (Figure 3a). Multiple primary cilia were 
detected by immunostaining (Figure 3B) and electron microscopy (Figure 3C) after 72 hours 
of treatment.
Concerning Taxol, the treatment of fibroblasts with various concentrations (1.25, 3.25, 
5.25, 6.25 and 12.5 nM) for 72 hours revealed a significantly higher incidence of primary cilia 
after treatment with 1.25 and 3.25 nM Taxol (~80%) (Figure 4A), as detected by 
immunostaining (Figure 4B) and electron microscopy (Figure 4C). However, this incidence 
rate was slightly decreased in the cells within the higher concentration range (5.25, 6.25 and 
12.5 nM) in comparison with the lower concentration range (1.25 and 3.25 nM), although 
without change when compared to the untreated cells. 
Interestingly, a complete absence of primary cilia was noted in MDA-MB-231 cells after 
treatment with either Doxorubicin (10, 20, 40, 80 and 120 nM) or Taxol (1.25, 3.25, 5.25, 
6.25 and 12.5 nM) for 72 hours, an effect that was repeated in BT-549 cells (Figure 5).
4 Discussion
In the present work we sought to assess determine the effect that the cytostatics Doxorubicin 
and Taxol could have on cytoskeletal stabilityprimary cilia incidence in triple negative breast 
cancer cells. We chose these cytostatics because they are commonly used in the treatment of 
breast cancer. On one hand, Doxorubicin (DOX) acts by intercalating into the DNA strands 
inhibiting topoisomerase II activity and thus inducing strand breaks when DNA is being 































































replicated; in addition, it also promotes the formation of reactive oxygen species (ROS), 
which are highly toxic. Taxol, on the other hand, inhibits microtubule depolymerization [19] , 
resulting in shorter primary cilia and affecting their frequency in the exposed cells [15] ; 
therefore, it was included as a negative control drug in our experiments.
Solid tumorstumours possess a characteristic absence or low incidence of primary cilia 
which, when present, may also have a compromised structure and function. However, some 
tumortumour types that are dependent upon the Hedgehog (Hh) signalingsignalling pathway 
often have an increased frequency of primary cilia [20, 21] . Further, several types of 
tumorstumours have been associated with altered Hh, Wnt, NOTCH and Hippo 
signalingsignalling pathways, which are related to primary cilia; therefore, compromised 
signal transduction could also be caused by defects in the formation, structure or function of 
primary cilia [22] .
Primary cilia normally occur in approximately 70% of fibroblasts and from 7 to 19% 
of epithelial cells from healthy breast tissue [11] . However, the study of 11 breast cancer cell 
lines revealed that primary cilia were only present in 4 of these and at the very low frequency 
of 0.3% - 4%; curiously, these cell lines had the shared characteristic of being basal B 
subtypes, which are analogous to triple negative breast cancer cells [11] . Regardless, primary 
cilia have been found in some cases of TNBC, which hints at the existence of several TNBC 
subtypes in which the reason for this exclusive presence of primary cilia is yet unclear. A 
possible explanation could be that these tumortumour subtypes are dependent upon the Hh 
signalingsignalling pathway and hence upon primary cilia, as it has been observed in most 
basal cell carcinomas and medulloblastomas [22] .
In the present study, the chemosensitive triple negative breast cancer cell lines BT-549 
and MDA-MB-231 were used, in addition to normal skin fibroblasts as a comparative control, 
to test the effect that these cytostatics could have on primary cilia incidence. The cell lines 
were treated with 10, 20, 40, 80 and 120 nM Doxorubicin and 1.25, 3.25, 5.25, 6.25 and 12.5 
nM Taxol for 72 hours to determine the dose atin which the cells would become affected by 
the cytostatic drug without compromising viability or inducing cell death.  
ConsistentlyAccordingly, the number of viable cells decreased with an increasing increased 
concentration of cytostatics, which also correlated with the increased percentage of dead cells 
(data not shown). 































































Regarding Taxol, the included cell lines showed consistently decreasing proliferation 
and viability as the dosage of Taxol increased; therefore, low doses of 1.25, 3.25, 6.25 and 
12.5 nM Taxol were chosen based on previous experiments [23] .
In our study, fibroblasts were treated with the mentioned dose range of Doxorubicin 
and Taxol Tto establish a their baseline effect of the cytostaticson Doxorubicin and Taxol on 
ciliogenesis, fibroblasts were treated first with the before mentioned dose range of 
Doxorubicin and Taxol. Concerning Doxorubicin, an even increment in primary cilia 
frequency was observed across the full dose range (10, 20, 40, 80 and 120 nM) after 72h of 
treatment, reaching a maximum value of 70% after a under a 120 nM dose. 
FurtherInterestingly, 20 to 40% of fibroblasts showed two or more cilia after treatment with 
doses of 20-120 nM, reaching the maximum value of 40% multi-ciliated cells after treatment 
with 80 nM. It must be mentioned that multi-ciliated cells also were in possession of multiple 
centrosomes, an effect that has also been observed in some tumortumour cells after exposure 
to cytostatics or ionizing radiation [7, 9] . The treatment of fibroblasts with Taxol also 
resulted in increased primary cilia frequency, reaching a value of 80% after 72h of treatment 
with 1.25 and 3.25 nM; however, exposure to the higher doses range (5.25, 6.25 and 12.5 nM) 
resulted in a slightly decreased primary cilia frequency in the treated fibroblasts when 
compared with to the lower dose range (1.25 and 3.25 nM), but not when compared against 
the untreated control. It must be highlighted that, unlike the treatment with Doxorubicin, the 
treatment of fibroblasts with Taxol did not result in multi-ciliated cells.
Once the baseline effect of Doxorubicin and Taxol was determined on healthy cells, 
we proceeded to test their effect on primary cilia frequency in the triple negative breast cancer 
cell lines MDA-MB-231 and BT-549. 
Unlike fibroblasts, however, the treatment of these cells lines MDA-MB-231 and BT-
549 with either Doxorubicin (10, 20, 40, 80, and 120 nM) or Taxol (1.25, 3.25, 5.25, 6.25, 
and 12.5 nM) resulted in the complete absence ofdid not increase the frequency of primary 
cilia, which was somewhat intriguing.
Based on previous results we were aware that primary cilia are absent or in very low 
percentage in the triple negative breast cancer cell lines BT-549 and MDA-MB-231 [11, 24, 
25] . This absence of primary cilia has; further, the reason for this absence has been associated 
with a loss of function mutation in the tumortumour suppressor gene p53 [26] . However, the 
effect that Doxorubicin could have on primary cilia frequency in these cell lines has been 
heretofore unreported. 































































A particular issue in this regard is that multiple primary cilia are associated with an 
abnormal number of centrosomes in the cell and, according to other unpublished results from 
our group, it appears that this is a relevant issue in understanding the relation between 
ciliogenesis and carcinogenesis. Elaborating in this regard, several tumorstumours and some 
ciliopathies [6, 7, 10] , possess a characteristic and aberrant number of centrosomes. Multiple 
centrosomes occur in tumortumour cells in which mutations of the p53, BRCA1 and BRCA2 
genes are present [27–29] . Often, the surface of cells with multiple centrosomes displays an 
increased number of primary cilia (2-6) with the same structure and similar length. Curiously, 
the total number of Smo receptors, serotonin type 6 receptors, fibrocystin protein, and Arl13b 
protein (ADP-ribosylation factor-like protein 13b) present on these multiple cilia remains the 
same as in single primary cilia. This suggests that since this number remains the same 
regardless of the number of cilia, the receptor and protein content along the total length of the 
primary cilia is greater, meaning that the amount of these proteins per unit of length in the 
primary cilia is smaller in multi-ciliated cases, thus resulting in a lower receptor density. Such 
dilution in receptor density can lead to weaker signalingsignalling stimuli [30] , which has 
been observed in the alternative Wnt signalingsignalling pathways of cells with two or more 
primary cilia [31] .
Primary cilia play an important role in cell growth and tissue homeostasis (Schneider 
et al. 2005) and, in normal cells, the development of primary cilia is a dynamic process whose 
formation can occur in either G0/G1 or, more commonly, during the S/G2 phases; however, 
and almost without exception, the cilium is absorbed before entering mitosis and reappears 
once again in post-cytokinetic phases of the cell cycle. This periodic cilium absorption is 
therefore related to the cell cycle and affects cell sensitivity to external signals associated with 
cilia receptors [32] . TNBC cells, however, are notorious for their lack of primary cilia, 
although they can sometimes occur with extremely low frequency [33] . Regardless, this low 
primary cilium frequency cannot be increased under serum starvation conditions in TNBC 
cells, which has been a proven method in healthy cells [11] . 
Our study reports the null effect of Doxorubicin or Taxol on the incidence of primary 
cilia in triple negative breast cancer cell lines BT-549 and MDA-MB-231. Previous reports 
had only addressed the use of taxanes and their effect on ciliary length in breast cancer cell 
lines but not of Doxorubicin, which has not been reported elsewhere. Further, we also report 
the presence of multiple primary cilia in breast fibroblasts induced by Doxorubicin which, to 
the best of our knowledge, is now reported for the first time. The null effect of these 































































cytostatics on primary cilia incidence in the evaluated TNBC cell lines, as opposed to their 
effect on healthy cells, hints at some larger mechanism at play that could be involved with the 
inherent characteristics of malignant cells; Under the observed circumstances, we could 
suggest that primary cilia are responsible for specific cell signaling events and cytoskeletal 
stability after chemotherapy, and could therefore be involved in the survival of TNBC cells; 
however, these considerations must be addressed further and more in depth before an accurate 
conclusion can be reached. We suggest that this increased primary cilia frequency could be 
used as a tool in other toxicological studies evaluating the toxicity of cytostatic drugs.
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Figure Legends
Figure Legends
Figure 1. WST-1 test after 72 hours of treatment with Doxorubicin (10, 20, 40, 80, and 120 
nM) in BT-549 (A), MDA-MB-231 (B), and fibroblasts (C).  WST-1 test after 72 hours of 
treatment with Taxol (1.25, 3.25, 5.25, 6.25, and 12.5 nM) in BT-549 (D), MDA-MB-231 (e), 
and fibroblasts (f) (60x). *P < 0.05 **P < 0.01 ***P < 0.001 vs. control group.
Figure 2. Panel (A) shows the percentage ciliated fibroblasts after treatment with various 
concentrations of Doxorubicin (10, 20, 40, 80 and 120 nM). (B) Control cells with primary 
cilia were observed after 72 hours of culture. (C) Primary cilia were observed 72 hours after 
treatment with 120 nM Doxorubicin. Representative immunofluorescence images of primary 
cilia: acetylated tubulin (red, axoneme), gamma-tubulin (green, basal body), nuclei (blue). (d) 
Longitudinal section of a primary cilium (arrow) in fibroblast control cells. The cilium 
emerges from a basal body (open arrows). The proximal region of the cilium is situated within 































































an invagination of the plasma membrane, a ciliary pocket (arrowheads). n – nucleus (Bar 500 
nm). (e) Transverse section of a primary cilium in fibroblasts after treatment with 40 nM 
Doxorubicin, showing the structure of its axoneme (arrows): nine microtubule doublets 
arranged at the periphery, an undeveloped central microtubule doublet. Outer plasma 
membrane of the ciliary pocket surrounding the cilium shaft (arrowheads). n – nucleus (Bar 
200 nm). *P < 0.05 **P < 0.01 ***P < 0.001 vs. control group (60x).
Figure 3. Panel (A) shows the percentage of multi-ciliated fibroblasts after treatment with 
various concentrations of Doxorubicin (10, 20, 40, 80 and 120 nM). (B) Multiple cilia were 
observed 72 hours after treatment with 80 nM Doxorubicin. Representative 
immunofluorescence images of primary cilia: acetylated tubulin (red, axoneme), gamma-
tubulin (green, basal body), nuclei (blue). (C) Transverse section of multiple cilia in 
fibroblasts after treatment with 80 nM of Doxorubicin reveals the structure of its axoneme 
(arrows). The outer plasma membrane of the ciliary pocket surrounds the cilium shaft 
(arrowheads). n – nucleus (Bar 1.5 nm). *P < 0.05 **P < 0.01 ***P < 0.001 vs. control group. 
Magnification (60x).
Figure 4. Panel (A) shows the percentage of cells with primary cilia in fibroblasts after 
treatment with various concentrations of Taxol (1.25, 3.25, 5.25, 6.25 and 12.5 nM). (B) 
Primary cilia were observed after 72 hours of treatment with 1.25 nM Taxol. Representative 
immunofluorescence images of primary cilia: acetylated tubulin (red, axoneme) and gamma-
tubulin (green, basal body), nuclei (blue). (C) TEM image of fibroblasts after treatment with 
1.25 nM Taxol shows the transverse section of a primary cilium (arrow), it contains six 
microtubule doublets arranged at the periphery and one centrally located microtubule doublet. 
The open arrows depict the outer plasma membrane of the ciliary pocket surrounding the 
cilium shaft (Bar 0.25 nm) (60x). *P < 0.05 **P < 0.01 ***P < 0.001 vs.  control group.
Figure 5. Representative immunofluorescence images of BT-549 and MDA-MB-231 cells: 
acetylated tubulin (red), nuclei (blue). Primary cilia are absent after 72 hours of treatment 
with Doxorubicin and Taxol in BT-549 and MDA-MB-231 (60x).
Figure 1 WST-1 test after 72 hours of treatment with Doxorubicin (10, 20, 40, 80, 120 nM) in 
BT-549 (A), MDA-MB-231 (B), and fibroblasts (C).  WST-1 test after 72 hours of treatment 
with Taxol (1.25, 3.25, 5.25, 6.25, 12.5 nM) in BT-549 (D), MDA-MB-231 (e), and 
fibroblasts (f) (60x). *P < 0.05 **P < 0.01 ***P < 0.001 vs. control group.































































Figure 2 Panel (A) shows the percentage of ciliated cells in fibroblasts after treatment with 
various concentrations of Doxorubicin (10, 20, 40, 80 and 120 nM). (B) Control cells with 
primary cilia were observed 72 hours of culture. (C) Primary cilia were observed 72 hours 
after treatment with 120 nM Doxorubicin. Representative images of primary cilia detected by 
immunofluorescence: acetylated tubulin (red, axoneme), gamma-tubulin (green, basal body), 
nuclei (blue). (d) Longitudinal section of a primary cilium (arrow) in fibroblast control cells. 
The cilium emerges from a basal body (open arrows). The proximal region of the cilium is 
situated within an invagination of the plasma membrane, a ciliary pocket (arrowheads). n – 
nucleus (Bar 500 nm). (e) Transverse section of a primary cilium in fibroblasts after treatment 
with 40 nM Doxorubicin, showing the structure of its axoneme (arrows): nine microtubule 
doublets arranged at the periphery, an undeveloped central microtubule doublet. Outer plasma 
membrane of the ciliary pocket surrounding the cilium shaft (arrowheads). n – nucleus (Bar 
200 nm). *P < 0.05 **P < 0.01 ***P < 0.001 vs. control group (60x).
Figure 3 Panel (A) shows the percentage of multiple cilia in fibroblasts after treatment with 
various concentrations of Doxorubicin (10, 20, 40, 80 and 120 nM). (B) Multiple cilia were 
observed 72 hours after treatment with 80 nM Doxorubicin. Representative images of primary 
cilia detected by immunofluorescence: acetylated tubulin (red, axoneme), gamma-tubulin 
(green, basal body), nuclei (blue). (C) Transverse section of multiple cilia in fibroblasts after 
treatment with 80 nM of Doxorubicin reveals the structure of its axoneme (arrows). The outer 
plasma membrane of the ciliary pocket surrounds the cilium shaft (arrowheads). n – nucleus 
(Bar 1.5 nm). *P < 0.05 **P < 0.01 ***P < 0.001 vs. control group. Magnification (60x).
Figure 4 Panel (A) shows the percentage of cells with primary cilia in fibroblasts after 
treatment with various concentrations of Taxol (1.25, 3.25, 5.25, 6.25 and 12.5 nM). (B) 
Primary cilia were observed 72 hours after treatment with 1.25 nM Taxol. Representative 
images of primary cilia detected by immunofluorescence: acetylated tubulin (red, axoneme) 
and gamma-tubulin (green, basal body), nuclei (blue). (C) TEM image of fibroblasts after 
treatment with 1.25 nM Taxol shows the transverse section of a primary cilium (arrow), it 
contains six microtubule doublets arranged at the periphery and one centrally located 
microtubule doublet. The open arrows depict the outer plasma membrane of the ciliary pocket 
surrounding the cilium shaft (Bar 0.25 nm) (60x). *P < 0.05 **P < 0.01 ***P < 0.001 vs.  
control group.































































Figure 5 Representative images of immunofluorescent staining of BT-549 and MDA-MB-
231 cells: acetylated tubulin (red), nuclei (blue). Primary cilia are absent after 72 hours 
treatment with Doxorubicin and Taxol in BT-549 and MDA-MB-231 (60x).































































Figure 1 WST-1 test after 72 hours of treatment with Doxorubicin (10, 20, 40, 80, 120 nM) in BT-549 (A), 
MDA-MB-231 (B), and fibroblasts (C).  WST-1 test after 72 hours of treatment with Taxol (1.25, 3.25, 5.25, 
6.25, 12.5 nM) in BT-549 (D), MDA-MB-231 (e), and fibroblasts (f) (60x). *P < 0.05 **P < 0.01 ***P < 
0.001 vs. control group. 
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Figure 2 Panel (A) shows the percentage of ciliated cells in fibroblasts after treatment with various 
concentrations of Doxorubicin (10, 20, 40, 80 and 120 nM). (B) Control cells with primary cilia were 
observed 72 hours of culture. (C) Primary cilia were observed 72 hours after treatment with 120 nM 
Doxorubicin. Representative images of primary cilia detected by immunofluorescence: acetylated tubulin 
(red, axoneme), gamma-tubulin (green, basal body), nuclei (blue). (d) Longitudinal section of a primary 
cilium (arrow) in fibroblast control cells. The cilium emerges from a basal body (open arrows). The proximal 
region of the cilium is situated within an invagination of the plasma membrane, a ciliary pocket 
(arrowheads). n – nucleus (Bar 500 nm). (e) Transverse section of a primary cilium in fibroblasts after 
treatment with 40 nM Doxorubicin, showing the structure of its axoneme (arrows): nine microtubule 
doublets arranged at the periphery, an undeveloped central microtubule doublet. Outer plasma membrane 
of the ciliary pocket surrounding the cilium shaft (arrowheads). n – nucleus (Bar 200 nm). *P < 0.05 **P < 
0.01 ***P < 0.001 vs. control group (60x). 
79x59mm (300 x 300 DPI) 































































Figure 3 Panel (A) shows the percentage of multiple cilia in fibroblasts after treatment with various 
concentrations of Doxorubicin (10, 20, 40, 80 and 120 nM). (B) Multiple cilia were observed 72 hours after 
treatment with 80 nM Doxorubicin. Representative images of primary cilia detected by immunofluorescence: 
acetylated tubulin (red, axoneme), gamma-tubulin (green, basal body), nuclei (blue). (C) Transverse section 
of multiple cilia in fibroblasts after treatment with 80 nM of Doxorubicin reveals the structure of its axoneme 
(arrows). The outer plasma membrane of the ciliary pocket surrounds the cilium shaft (arrowheads). n – 
nucleus (Bar 1.5 nm). *P < 0.05 **P < 0.01 ***P < 0.001 vs. control group. Magnification (60x). 
80x60mm (300 x 300 DPI) 































































Figure 4 Panel (A) shows the percentage of cells with primary cilia in fibroblasts after treatment with various 
concentrations of Taxol (1.25, 3.25, 5.25, 6.25 and 12.5 nM). (B) Primary cilia were observed 72 hours after 
treatment with 1.25 nM Taxol. Representative images of primary cilia detected by immunofluorescence: 
acetylated tubulin (red, axoneme) and gamma-tubulin (green, basal body), nuclei (blue). (C) TEM image of 
fibroblasts after treatment with 1.25 nM Taxol shows the transverse section of a primary cilium (arrow), it 
contains six microtubule doublets arranged at the periphery and one centrally located microtubule doublet. 
The open arrows depict the outer plasma membrane of the ciliary pocket surrounding the cilium shaft (Bar 
0.25 nm) (60x). *P < 0.05 **P < 0.01 ***P < 0.001 vs.  control group. 
78x56mm (300 x 300 DPI) 































































Figure 5 Representative images of immunofluorescent staining of BT-549 and MDA-MB-231 cells: acetylated 
tubulin (red), nuclei (blue). Primary cilia are absent after 72 hours treatment with Doxorubicin and Taxol in 
BT-549 and MDA-MB-231 (60x). 
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Author's Response to Decision Letter for (JCMM-03-2019-024)
Primary cilia - an in vitro model to evaluate the toxic effect of cytostatics on cytoskeletal stability.
April 29th, 2019 
Hradec Králové, Czech Republic 
Dear Editor; 
We thank you for your consideration and the reviewers for their input and valuable comments. We have 
addressed the shortcoming of our manuscript “Primary cilia - an in vitro model to evaluate the toxic 
effect of cytostatics on cytoskeletal stability” as follows: 
Reviewer: 1 
Comments to the Author 
In the submitted manuscript, the authors claim to use the incidence of ciliated cells as a marker for the 
effectiveness of cytostatic drugs in the context of chemotherapy, specifically for triple-negative forms of 
breast cancer. 
Unfortunately, the authors do not yet provide sufficient evidence to substantiate or refute their claim. 
There are at least two major areas of confusion that must be clarified prior to acceptance: 
We agree with the reviewer on this point and have modified the text of the manuscript as well as its title 
so it reflects its content more accurately; the new title of the manuscript is: “The toxic effect of 
cytostatics on primary cilia frequency and multiciliation”. We added that this is the first time that 
doxorubicin has been used in this context and the first time that multiciliation induced by doxorubicin is 
reported; also, we clarify that the lack of primary cilia after treatment with cytostatics is rather an 
interesting observation in TNBC cells which might, or might not, be relevant to their malignant 
characteristics and needs to be researched further. 
1) The connection between ciliogenesis and the cell cycle potentially interferes with the author's 
conclusions. This shortcoming appears in various places throughout the manuscript, for example a) The 
section on cell culture has an unclear timeline: how long does ciliogenesis 'normally' take? When was 
the serum concentration reduced (to promote differentiation and ciliogenesis) if it was reduced? When 
was the taxol/doxorubicin introduced in the context of ciliogenesis? 
There is an undeniable and tight relation between the cell cycle and ciliogenesis that has been described 
extensively elsewhere. Elaborating a bit further, ciliogenesis usually occurs during the G0/G1 stages of 
the cell cycle, and sometimes during G2, to be later resorbed during mitosis. To the best of our 
knowledge, there are no available reports describing the time evolution of primary cilia; further, such 






























































timing was not the aim of the present study but rather to measure the incidence of ciliated cells after 
treatment with cytostatics. We modified the text so that the experimental treatment of the cells (24 
hours after plating) for treatment with cytostatics is clear. Although serum starvation has been the 
standard in primary cilia study, we did not use it in this study. Also, we are not inducing cell 
differentiation. 
2) Confusion between the cell survival rate and ciliation rate. For example, the authors claim that after 
treatment, the number of cells that survive *decrease* and the fraction of ciliated cells *increase*, but 
does that increased fraction account for the overall decrease in cell number? Also, the exclusive use of 
fixation prior to cilia counting is problematic, as cilia often break during the fixation step- live cell 
imaging is superior. The authors also state that primary cilia are absent in the cell lines *without* 
treatment (lines 34-35, page 9) and then make claims about the low fraction of ciliated cells after 
treatment, which doesn't make sense. 
The reviewer is right to some extent in this regard, as it could be confusing; however, this increment in 
primary cilia incidence is measured in percentage, that is, its numerical value is relative not arithmetic. 
Regarding fixation, there are previous reports indicating that the use of PFA as a fixative is acceptable in 
the detection of primary cilia allowing the good resolution of immunofluorescent staining (Biology Open 
5:1001-9; 2016) and is not different from other fixation methods when immunolabeling Acetylated-α-
tubulin for primary cilia detection like we did in this study (Cilia 6:5; 2017). Regarding the low-fraction of 
ciliated cells; cancer cells are widely heterogenous and one of their characteristics is that they can be 
either ciliated or not, depending of the cancer cell type. In this study we used the cell lines BT-549 and 
MDA-MB-231, which are similar to triple negative breast cancer cells, which are notorious for their low 
incidence or absent primary cilia. Having said this, we did not detect any primary cilia in the TNBC cell 
lines, only in breast fibroblasts. The lower percentage of ciliated cells in untreated fibroblasts can be 
explained by their lack of synchronization, which is then modified under the presence of cytostatics. 
That said, the finding that doxorubicin results in multiciliated cells is interesting and deserves additional 
discussion, perhaps referencing the example of multiciliated airway cells (even though these are motile 
cilia). 
We appreciate the kind opinion of our reviewer and fully agree with him/her in this regard. Having said 
this, we cannot directly correlate the effect of the cytostatics on multiciliation in the treated cells of this 
study with naturally multiciliated airway cells, particularly because they serve different purposes, their 
function is linked with other signaling pathways, and are not structurally similar. 
We thank once again to our reviewer and hope the made changes to our manuscript will be sufficient 
for its publication in your journal. We will happily oblige should further clarification be need on our 
part. 
Best and kind regards, 






























































Prof. Stanislav Filip, MD., Ph.D. 
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The primary cilium is considered as a key component of morphological cellular stability. 
However, cancer cells are notorious for lacking primary cilia in most cases, depending upon 
the tumour type. Previous reports have shown the effect of starvation and cytostatics on 
ciliogenesis in normal and cancer cells although with limited success, especially when 
concerning the latter. In this study we evaluated the presence and frequency of primary cilia in 
breast fibroblasts and in triple negative breast cancer cells after treatment with cytostatics 
finding that, in the case of breast fibroblasts, primary cilia were detected at their highest 
incidence 72 hours after treatment with 120 nM doxorubicin. Further, multiciliated cells were 
also detected after treatment with 80 nM doxorubicin. On the other hand, treatment with taxol 
increased the number of ciliated cells only at low concentrations (1.25 and 3.25 nM) and did 
not induce multiciliation. Interestingly, triple negative breast cancer cells did not present 
primary cilia after treatment with either doxorubicin or taxol. This is the first study reporting 
presence of multiple primary cilia in breast fibroblasts induced by Doxorubicin. However, the 
null effect of these cytostatics on primary cilia incidence in the evaluated TNBC cell lines 
requires further research. 
Key words: Primary cilium, multiple cilia, cytostatics, toxicity, cell line .
































































Primary cilium, an organelle found on nearly every cell in the human body, typically serves as 
a mechanical sensory tool; further, it is also involved in cell proliferation and embryonic 
development. This organelle is dynamically regulated during the cell cycle, appearing during 
the G0/G1 phases and resorbed prior to mitosis [1] . The exact solubilization moment of primary 
cilia is determined by cell type and the expression of genes affecting resorption, such as Aurora 
A, Plk1, TcTex-1 [2, 3] . Usually, a cell has only one primary cilium which, as previously 
mentioned, is involved in morphogenesis, cell proliferation and differentiation signalling [4, 5] 
. Should there be a multiplication of centrosomes, a higher number of primary cilia will appear 
on the surface of cells as well, often bearing the same length and construction design, and 
spawning from the same ciliary pocket; however, the presence of multiple cilia has been mostly 
recorded in solid tumours [6, 7]  after exposure to ionizing irradiation [8, 9]  or in ciliopathies 
[10] . Typically, primary cilia are always observed in myoepithelial cells and fibroblasts and 
with low incidence in luminal epithelium cells. Regarding cancer cells, a study of 26 breast 
cancer biopsy samples revealed the presence of primary cilia only on exceptional cases, 
especially in epithelial cells [11] . 
Basal subtype B tumours, a classification of triple negative breast carcinomas (TNBC), is 
characterized by the absence of oestrogen, progesterone, and Her2/neu receptors [12], as well 
as by the rare presence of primary cilia. Among breast cancer tumours, TNBC has an estimated 
incidence of 10-20%, although from a histological point of view TNBCs are little differentiated 
and are often included in basal-like subgroups. From a clinical standpoint, these tumours are 
frequently resistant to treatment, have quick progression, low 5-year survival rate, increased 
local recurrence, and are highly metastatic. This kind of tumours can be observed at any age; 
however, they mostly occur accompanied by BRCA1 mutations in younger women (>40 years 
of age) [13]. Chemotherapy is the treatment of choice for triple negative breast cancer patients, 
of which Doxorubicin and Taxol are the standard chemotherapeutic agents used as anticancer 
therapy in combination with α-HER2/neu receptor targeted therapy. Doxorubicin belongs to the 
anthracyclines group, whereas Taxol is considered as a taxane. The former is an effective 
intercalating cytotoxic agent used in the treatment of various tumour types and commonly used 
in combination with the latter in adjuvant and neoadjuvant therapeutic strategies for breast 
cancer patients [14] . 































































Previous research on the effect of cytostatics on primary cilia has focused in the effects of Taxol 
over the elongation and shortening of primary cilia. In a study by Sharma et al., Taxol was 
shown to block the emergence of primary cilia in mammalian cell cultures [15]. However, low 
concentrations result in an increased quantity of free tubulin subunits in the cytosol, leading to 
enlarged primary cilia [16, 17]. Ongoing research highlights two important questions in the cell 
biology of cancer and primary cilia: 1) the significance of having primary cilia in normal cells, 
and 2) the loss of primary cilia in cancer cells and its relation to drug resistance [18] . Therefore, 
the increased primary cilia frequency induced by cytostatics could be used in other studies 
trying to assess the toxicity of these drugs. 
2 Material and methods
2.1 Cell culture
Unless otherwise stated, all standard chemicals and antibodies were purchased from Sigma-
Aldrich, Czech Republic. In this study, TNBC cell lines BT-549 (ATCC, USA) and MDA-MB-
231 were used (kindly supplied by Mgr. Jaroslav Truksa, Ph.D., Laboratory of Tumor 
Resistance, Institute of Biotechnology CAS, Prague), as well as skin fibroblasts. BT-549 cells 
were cultured in DMEM 10% FBS (PAA, USA), 2% glutamine (Gibco, UK), 1% 
penicillin/streptomycin (Gibco, UK), 0.023 IU/ml insulin and incubated in a 5% CO2 
atmosphere at 37°C. MDA-MB-231 and fibroblasts were cultured in DMEM, 10% FBS (PAA, 
USA), 2% glutamine (Gibco, UK), 1% penicillin/streptomycin (Gibco, UK) and incubated in a 
5% CO2 atmosphere at 37°C. All cell lines were used until 10th to 12th passage and medium was 
replaced every two days for all experiments.
2.2 Skin fibroblasts
Human fibroblasts were isolated from skin biopsies obtained in accordance and approved by 
the Ethics Committee of the University Hospital Hradec Kralove, Czech Republic and the 
European Ethics committee under the directive approved on 10th July 2014 (Reference/license 
number: 201407 S12P). Donor patients signed an informed consent allowing us to work with 
the obtained samples. To isolate the fibroblasts, skin biopsies were kept in a basic solution (30 
ml/2g of tissue) after surgery and transported to the laboratory, where the biopsies were washed 
in PBS and the subcutaneous tissue was removed. Each individual tissue sample was incubated 
in 5 ml of a 2U/ml dispase solution (Gibco, UK) for 18 hours at 4°C. After incubation, the 































































samples were washed 3 times in PBS at room temperature (22°C). The dermis was separated 
from the epidermis using tweezers, washed in PBS and cut into small sections (<5mm2). 
Afterwards, the tissue was incubated in 10 ml of digestion solution (1g tissue/10 ml) in a 
rotating incubator at 37°C/6 g. After 4 hours, the samples were filtered through a 40 μm strainer 
into a new sterile 50 ml tube. The cell number was determined from this suspension and 
centrifuged for 10 min/150 g. The supernatant was decanted and the cell pellet was resuspended 
in culture media, plated in a T-75 flask (1x105 cells per flask) and incubated in a 5% CO2 
atmosphere at 37°C for 14 days.
2.3 Cytostatic drugs
Doxorubicin and Taxol were dissolved in 0.5% DMSO and kept in 1 mM stock solutions. 
Doxorubicin and Taxol were diluted in culture media before use at a ratio of 1:100 and 1:1000, 
respectively.
2.4 Cell treatment and Immunofluorescence
MDA-MB-231, BT-549, and fibroblasts cells were cultured in 6-well plates at a density of 3 x 
105 cells per well and incubated at 37°C/5% CO2 for 24h, each well contained a gelatine coated 
coverslip. After this period, the cells were treated with Doxorubicin (10, 20, 40, 80 and 120 
nM) or Taxol (1.25, 3.25, 5.25, 6.25, and 12.5 nM) for 72 hours. Control cells were kept under 
the same conditions in culture media with or without DMSO (0.5%). After treatment, the cells 
were fixed with 4% paraformaldehyde for 10 min at room temperature and washed three times 
with PBS. Immunostaining was performed as follows: cells were blocked with goat serum 
(Jackson Immunoresearch, USA) 1:20 for 30 minutes; anti-acetylated tubulin 1:800 for 1 hour; 
anti-gamma tubulin  1:500 for 1 hour; Cy3-conjugated donkey anti-mouse secondary antibody 
1:300 for 45 minutes in the dark; Alexa 488 conjugated donkey anti-rabbit secondary antibody 
(JacksonImmunoresearch, USA) 1:300 for 45 min in the dark. Imaging analysis was performed 
using a Nikon Eclipse fluorescence microscope (Prague, Czech Republic) observed with an oil-
immersion 60X objective. All experiments were performed in triplicate.
2.5 Cytotoxicity test
A WST-1 test (Roche; Basel, Switzerland) was used to determine cell viability after treatment 
with Doxorubicin (10, 20, 40, 80, 120 nM) or Taxol (1.25, 3.25, 5.25, 6.25, 12.5 nM). All cell 
lines were plated and treated in a 96-well-plate (1 x 103 cells per well), and incubated at 
37°C/5%CO2 for 24h. After 72 h, 10µL of WST-1 reagent was added and incubated for 3 h at 































































37°C/5% CO2 and analysed in a Tecan SpectraFluor Plus spectrometer (Tecan Austria GmbH; 
Grödig, Austria) at a wavelength of 440 nm. All experiments were performed in triplicate.
2.6 Transmission electron microscopy (TEM)
Fibroblasts were fixed in 3% glutaraldehyde (in 0.1 M cacodylate buffer, pH 7.2) for 5 min. at 
37°C and then for 3 h at room temperature, washed in cacodylate buffer (0.1 M, pH 7.2) and 
post-fixed in 1% OsO4 (in 0.1 M cacodylate buffer, pH 7.2) for 1 h at room temperature. After 
rinsing in cacodylate buffer (0.1 M, pH 7.2), the cells were dehydrated in graded alcohols (50%, 
75%, 96%, 100%), cleared in propylene oxide and embedded in a mixture of Epon 812 and 
Durcupan (Sigma; polymerization for 3 days at 60°C). Semi-thin sections were stained with 
toluidine blue. Ultra-thin sections were cut on an Ultrotome Nova (LKB, Sweden), mounted 
into formvar carbon-coated copper grids, counterstained with uranyl acetate and lead citrate 
and examined in a JEOL JEM-1400Plus transmission electron microscope (at 120 kV JEOL, 
Japan). Images were captured with integrated 8Mpix CCD camera and software (JEOL, Japan).
2.7 Statistical analysis
Graphs were made using the GraphPad Prism 6 biostatistics software (GraphPad Software, 
USA). The statistical analysis between the evaluated groups was performed using one-way 
ANOVA followed by a post-hoc Tukey test (p<0.05).
3 Results
3.1 Proliferation and viability of BT-549, MDA-MB-231, and fibroblasts after 
treatment with Doxorubicin and Taxol 
Cytostatics are known inhibitors of cell viability and proliferation, therefore we had to 
determine a suitable concentration in which the cells would stop proliferating without losing 
viability. To achieve this purpose, the MDA-MB-231, BT-549 and fibroblast cells were 
maintained with Doxorubicin or Taxol at various concentrations (10, 20, 40, 80 and 120 nM 
and 1.25, 3.25, 5.25, 6.25 and 12.5 nM, respectively), followed by a WST-1 test after 72 hours 
of treatment. The number of living cells was significantly lower after Doxorubicin (Figure 1A-
C) and Taxol (Figure 1D-F) treatment across all cell lines.































































3.2 Primary cilia incidence and multi-ciliation induced by the cytostatics 
Doxorubicin and Taxol
Regarding Doxorubicin, the number of fibroblasts with primary cilia increased to ~70%, in 
comparison with control untreated cells, after 72 hours of treatment with various concentrations 
of this cytostatic (10, 20, 40, 80 and 120 nM), observing a higher incidence after treatment with 
120 nM Doxorubicin. Overall, this effect could be observed evenly across the entire dose range 
used in this study (Figure 2A). After 72 hours of treatment, primary cilia were detected by 
immunostaining (Figure 2B – control cells; Figure 2C – 120nM Doxorubicin) and electron 
microscopy (Figure 2D – control; Figure 2E – 120 nM Doxorubicin). Interestingly, ~20-40% 
of fibroblasts treated with 20-120 nM Doxorubicin showed two or more cilia after 72 hours of 
treatment, observing a higher number of multi-ciliated cells at a dose of 80 nM Doxorubicin 
(~40%; Figure 3A). However, no multi-ciliated cells could be observed after treatment with 10 
nM Doxorubicin or in untreated cells (Figure 3a). Multiple primary cilia were detected by 
immunostaining (Figure 3B) and electron microscopy (Figure 3C) after 72 hours of treatment.
Concerning Taxol, the treatment of fibroblasts with various concentrations (1.25, 3.25, 
5.25, 6.25 and 12.5 nM) for 72 hours revealed a significantly higher incidence of primary cilia 
after treatment with 1.25 and 3.25 nM Taxol (~80%) (Figure 4A), as detected by 
immunostaining (Figure 4B) and electron microscopy (Figure 4C). However, this incidence rate 
was slightly decreased in the cells within the higher concentration range (5.25, 6.25 and 12.5 
nM), although without change when compared to the untreated cells. 
Interestingly, a complete absence of primary cilia was noted in MDA-MB-231 cells after 
treatment with either Doxorubicin (10, 20, 40, 80 and 120 nM) or Taxol (1.25, 3.25, 5.25, 6.25 
and 12.5 nM) for 72 hours, an effect that was repeated in BT-549 cells (Figure 5).
4 Discussion
In the present work we sought to determine the effect that the cytostatics Doxorubicin and Taxol 
could have on primary cilia incidence in triple negative breast cancer cells. We chose these 
cytostatics because they are commonly used in the treatment of breast cancer. On one hand, 
Doxorubicin (DOX) acts by intercalating into the DNA strands inhibiting topoisomerase II 
activity and thus inducing strand breaks when DNA is being replicated; in addition, it also 
promotes the formation of reactive oxygen species (ROS), which are highly toxic. Taxol, on 
the other hand, inhibits microtubule depolymerization [19], resulting in shorter primary cilia 































































and affecting their frequency in the exposed cells [15] ; therefore, it was included as a negative 
control drug in our experiments.
Solid tumours possess a characteristic absence or low incidence of primary cilia which, 
when present, may also have a compromised structure and function. However, some tumour 
types that are dependent upon the Hedgehog (Hh) signalling pathway often have an increased 
frequency of primary cilia [20, 21]. Further, several types of tumours have been associated with 
altered Hh, Wnt, NOTCH and Hippo signalling pathways, which are related to primary cilia; 
therefore, compromised signal transduction could also be caused by defects in the formation, 
structure or function of primary cilia [22] .
Primary cilia normally occur in approximately 70% of fibroblasts and from 7 to 19% of 
epithelial cells from healthy breast tissue [11] . However, the study of 11 breast cancer cell lines 
revealed that primary cilia were only present in 4 of these and at the very low frequency of 
0.3% - 4%; curiously, these cell lines had the shared characteristic of being basal B subtypes, 
which are analogous to triple negative breast cancer cells [11]. Regardless, primary cilia have 
been found in some cases of TNBC, which hints at the existence of several TNBC subtypes in 
which the reason for this exclusive presence of primary cilia is yet unclear. A possible 
explanation could be that these tumour subtypes are dependent upon the Hh signalling pathway 
and hence upon primary cilia, as it has been observed in most basal cell carcinomas and 
medulloblastomas [22] .
In the present study, the chemosensitive triple negative breast cancer cell lines BT-549 
and MDA-MB-231 were used, in addition to normal skin fibroblasts as a comparative control, 
to test the effect that these cytostatics could have on primary cilia incidence. The cell lines were 
treated with 10, 20, 40, 80 and 120 nM Doxorubicin and 1.25, 3.25, 5.25, 6.25 and 12.5 nM 
Taxol for 72 hours to determine the dose in which the cells would become affected by the 
cytostatic drug without compromising viability or inducing cell death. Accordingly, the number 
of viable cells decreased with an increased concentration of cytostatics. 
Regarding Taxol, the included cell lines showed consistently decreasing proliferation 
and viability as the dosage of Taxol increased; therefore, low doses of 1.25, 3.25, 6.25 and 12.5 
nM Taxol were chosen based on previous experiments [23] .
In our study, fibroblasts were treated with the mentioned dose range of Doxorubicin and 
Taxol to establish their baseline effect on ciliogenesis. Concerning Doxorubicin, an even 
increment in primary cilia frequency was observed across the full dose range (10, 20, 40, 80 
and 120 nM) after 72h of treatment, reaching a maximum value of 70% after under a 120 nM 































































dose. Interestingly, 20 to 40% of fibroblasts showed two or more cilia after treatment with doses 
of 20-120 nM, reaching the maximum value of 40% multiciliated cells after treatment with 80 
nM. It must be mentioned that multiciliated cells also were in possession of multiple 
centrosomes, an effect that has also been observed in some tumour cells after exposure to 
cytostatics or ionizing radiation [7, 9]. The treatment with Taxol also resulted in increased 
primary cilia frequency, reaching a value of 80% after 72h of treatment with 1.25 and 3.25 nM; 
however, exposure to higher doses (5.25, 6.25 and 12.5 nM) resulted in a slightly decreased 
primary cilia frequency in the treated fibroblasts when compared to the lower dose range (1.25 
and 3.25 nM) but not when compared against the untreated control. It must be highlighted that, 
unlike the treatment with Doxorubicin, the treatment with Taxol did not result in multiciliated 
cells.
Once the baseline effect of Doxorubicin and Taxol was determined on healthy cells, we 
proceeded to test their effect on primary cilia frequency in the triple negative breast cancer cell 
lines MDA-MB-231 and BT-549. Unlike fibroblasts, however, the treatment of these cells with 
either Doxorubicin (10, 20, 40, 80, and 120 nM) or Taxol (1.25, 3.25, 5.25, 6.25, and 12.5 nM) 
did not increase the frequency of primary cilia, which was somewhat intriguing.
Based on previous results we were aware that primary cilia are absent or in very low percentage 
in the triple negative breast cancer cell lines BT-549 and MDA-MB-231 [11, 24, 25]. This 
absence of primary cilia has been associated with a loss of function mutation in the tumour 
suppressor gene p53 [26]. However, the effect that Doxorubicin could have on primary cilia 
frequency in these cell lines has been heretofore unreported. 
A particular issue in this regard is that multiple primary cilia are associated with an 
abnormal number of centrosomes in the cell and, according to other unpublished results from 
our group, it appears that this is a relevant issue in understanding the relation between 
ciliogenesis and carcinogenesis. Elaborating in this regard, several tumours and some 
ciliopathies [6, 7, 10] possess a characteristic and aberrant number of centrosomes. Multiple 
centrosomes occur in tumour cells in which mutations of the p53, BRCA1 and BRCA2 genes 
are present [27–29]. Often, the surface of cells with multiple centrosomes display an increased 
number of primary cilia (2-6) with the same structure and similar length. Curiously, the total 
number of Smo receptors, serotonin type 6 receptors, fibrocystin protein, and Arl13b protein 
(ADP-ribosylation factor-like protein 13b) present on these multiple cilia remains the same as 
in single primary cilia. This suggests that since this number remains the same regardless of the 
number of cilia, the receptor and protein content along the total length of the primary cilia is 































































greater, meaning that the amount of these proteins per unit of length in the primary cilia is 
smaller in multiciliated cases, thus resulting in a lower receptor density. Such dilution in 
receptor density can lead to weaker signalling stimuli [30], which has been observed in the 
alternative Wnt signalling pathways of cells with two or more primary cilia [31].
Primary cilia play an important role in cell growth and tissue homeostasis (Schneider et 
al. 2005) and, in normal cells, the development of primary cilia is a dynamic process whose 
formation can occur in either G0/G1 or, more commonly, during the S/G2 phases; however, 
and almost without exception, the cilium is absorbed before entering mitosis and reappears once 
again in post-cytokinetic phases of the cell cycle. This periodic cilium absorption is therefore 
related to the cell cycle and affects cell sensitivity to external signals associated with cilia 
receptors [32]. TNBC cells, however, are notorious for their lack of primary cilia, although they 
can sometimes occur with extremely low frequency [33]. Regardless, this low primary cilium 
frequency cannot be increased under serum starvation conditions in TNBC cells, which has 
been a proven method in healthy cells [11]. 
Our study reports the null eff ct of Doxorubicin or Taxol on the incidence of primary 
cilia in triple negative breast cancer cell lines BT-549 and MDA-MB-231. Previous reports had 
only addressed the use of taxanes and thei  effect on ciliary length in breast cancer cell lines 
but not of Doxorubicin, which has not been reported elsewhere. Further, we also report the 
presence of multiple primary cilia in breast fibroblasts induced by Doxorubicin which, to the 
best of our knowledge, is now reported for the first time. The null effect of these cytostatics on 
primary cilia incidence in the evaluated TNBC cell lines, as opposed to their effect on healthy 
cells, hints at some larger mechanism at play that could be involved with the inherent 
characteristics of malignant cells; however, these considerations must be addressed further and 
more in depth before an accurate conclusion can be reached. 
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Figure and Legends
Figure 1. WST-1 test after 72 hours of treatment with Doxorubicin (10, 20, 40, 80, and 120 































































nM) in BT-549 (A), MDA-MB-231 (B), and fibroblasts (C).  WST-1 test after 72 hours of 
treatment with Taxol (1.25, 3.25, 5.25, 6.25, and 12.5 nM) in BT-549 (D), MDA-MB-231 (e), 
and fibroblasts (f) (60x). *P < 0.05 **P < 0.01 ***P < 0.001 vs. control group.
Figure 2. Panel (A) shows the percentage ciliated fibroblasts after treatment with various 
concentrations of Doxorubicin (10, 20, 40, 80 and 120 nM). (B) Control cells with primary cilia 
were observed after 72 hours of culture. (C) Primary cilia were observed 72 hours after 
treatment with 120 nM Doxorubicin. Representative immunofluorescence images of primary 
cilia: acetylated tubulin (red, axoneme), gamma-tubulin (green, basal body), nuclei (blue). (d) 
Longitudinal section of a primary cilium (arrow) in fibroblast control cells. The cilium emerges 
from a basal body (open arrows). The proximal region of the cilium is situated within an 
invagination of the plasma membrane, a ciliary pocket (arrowheads). n – nucleus (Bar 500 nm). 
(e) Transverse section of a primary cilium in fibroblasts after treatment with 40 nM 
Doxorubicin, showing the structure of its axoneme (arrows): nine microtubule doublets 
arranged at the periphery, an undeveloped central microtubule doublet. Outer plasma membrane 
of the ciliary pocket surrounding the cilium shaft (arrowheads). n – nucleus (Bar 200 nm). *P 
< 0.05 **P < 0.01 ***P < 0.001 vs. control group (60x).
Figure 3. Panel (A) shows the percentage of multi-ciliated fibroblasts after treatment with 
various concentrations of Doxorubicin (10, 20, 40, 80 and 120 nM). (B) Multiple cilia were 
observed 72 hours after treatment with 80 nM Doxorubicin. Representative 
immunofluorescence images of primary cilia: acetylated tubulin (red, axoneme), gamma-
tubulin (green, basal body), nuclei (blue). (C) Transverse section of multiple cilia in fibroblasts 
after treatment with 80 nM of Doxorubicin reveals the structure of its axoneme (arrows). The 
outer plasma membrane of the ciliary pocket surrounds the cilium shaft (arrowheads). n – 
nucleus (Bar 1.5 nm). *P < 0.05 **P < 0.01 ***P < 0.001 vs. control group. Magnification 
(60x).
Figure 4. Panel (A) shows the percentage of cells with primary cilia in fibroblasts after 
treatment with various concentrations of Taxol (1.25, 3.25, 5.25, 6.25 and 12.5 nM). (B) 
Primary cilia were observed after 72 hours of treatment with 1.25 nM Taxol. Representative 
immunofluorescence images of primary cilia: acetylated tubulin (red, axoneme) and gamma-
tubulin (green, basal body), nuclei (blue). (C) TEM image of fibroblasts after treatment with 
1.25 nM Taxol shows the transverse section of a primary cilium (arrow), it contains six 































































microtubule doublets arranged at the periphery and one centrally located microtubule doublet. 
The open arrows depict the outer plasma membrane of the ciliary pocket surrounding the cilium 
shaft (Bar 0.25 nm) (60x). *P < 0.05 **P < 0.01 ***P < 0.001 vs.  control group.
Figure 5. Representative immunofluorescence images of BT-549 and MDA-MB-231 cells: 
acetylated tubulin (red), nuclei (blue). Primary cilia are absent after 72 hours of treatment with 
Doxorubicin and Taxol in BT-549 and MDA-MB-231 (60x).
xxxxxxxtreatment with Taxol (1.25, 3.25, 5.25, 6.25, and 12.5 nM) in BT-549 (D), MDA-MB-
231 (e), and fibroblasts (f) (60x). *P < 0.05 **P < 0.01 ***P < 0.001 vs. control group.
Figure 2. Panel (A) shows the percentage ciliated fibroblasts after treatment with various 
concentrations of Doxorubicin (10, 20, 40, 80 and 120 nM). (B) Control cells with primary cilia 
were observed after 72 hours of culture. (C) Primary cilia were observed 72 hours after 
treatment with 120 nM Doxorubicin. Representative immunofluorescence images of primary 
cilia: acetylated tubulin (red, axoneme), gamma-tubulin (green, basal body), nuclei (blue). (d) 
Longitudinal section of a primary cilium (arrow) in fibroblast control cells. The cilium emerges 
from a basal body (open arrows). The proximal region of the cilium is situated within an 
invagination of the plasma membrane, a ciliary pocket (arrowheads). n – nucleus (Bar 500 nm). 
(e) Transverse section of a primary cilium in fibroblasts after treatment with 40 nM 
Doxorubicin, showing the structure of its axoneme (arrows): nine microtubule doublets 
arranged at the periphery, an undeveloped central microtubule doublet. Outer plasma membrane 
of the ciliary pocket surrounding the cilium shaft (arrowheads). n – nucleus (Bar 200 nm). *P 
< 0.05 **P < 0.01 ***P < 0.001 vs. control group (60x).
Figure 3. Panel (A) shows the percentage of multi-ciliated fibroblasts after treatment with 
various concentrations of Doxorubicin (10, 20, 40, 80 and 120 nM). (B) Multiple cilia were 
observed 72 hours after treatment with 80 nM Doxorubicin. Representative 
immunofluorescence images of primary cilia: acetylated tubulin (red, axoneme), gamma-
tubulin (green, basal body), nuclei (blue). (C) Transverse section of multiple cilia in fibroblasts 
after treatment with 80 nM of Doxorubicin reveals the structure of its axoneme (arrows). The 
outer plasma membrane of the ciliary pocket surrounds the cilium shaft (arrowheads). n – 
nucleus (Bar 1.5 nm). *P < 0.05 **P < 0.01 ***P < 0.001 vs. control group. Magnification 
(60x).































































Figure 4. Panel (A) shows the percentage of cells with primary cilia in fibroblasts after 
treatment with various concentrations of Taxol (1.25, 3.25, 5.25, 6.25 and 12.5 nM). (B) 
Primary cilia were observed after 72 hours of treatment with 1.25 nM Taxol. Representative 
immunofluorescence images of primary cilia: acetylated tubulin (red, axoneme) and gamma-
tubulin (green, basal body), nuclei (blue). (C) TEM image of fibroblasts after treatment with 
1.25 nM Taxol shows the transverse section of a primary cilium (arrow), it contains six 
microtubule doublets arranged at the periphery and one centrally located microtubule doublet. 
The open arrows depict the outer plasma membrane of the ciliary pocket surrounding the cilium 
shaft (Bar 0.25 nm) (60x). *P < 0.05 **P < 0.01 ***P < 0.001 vs.  control group.
Figure 5. Representative immunofluorescence images of BT-549 and MDA-MB-231 cells: 
acetylated tubulin (red), nuclei (blue). Primary cilia are absent after 72 hours of treatment with 
Doxorubicin and Taxol in BT-549 and MDA-MB-231 (60x).
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